Clinical experience with deslorelin (ovuplantTM) in a kentucky thoroughbred broodmare practice (1999) |
| |
| Affiliation: | 1. Center for Infectious Disease Research, Seattle, WA 98109, USA;2. Department of Global Health, University of Washington, Seattle, WA 98195, USA;1. Silesian University of Technology, Faculty of Chemistry, Strzody 9, Gliwice, 44-100, Poland;2. PPSM, CNRS UMR8531, ENS Cachan, 61 Avenue du President Wilson, Cachan, 94235, France;3. Centre of Polymer and Carbon Materials, Polish Academy of Sciences, M. Curie-Sklodowska 34, Zabrze, 41-819, Poland;1. Department of Large Animal Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA;2. Department of Infectious Diseases and Pathology, College of Veterinary Medicine, University of Florida, Gainesville, Florida, USA;3. Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA;4. Equine Reproduction Center, Peterson & Smith Equine Hospital, Ocala, Florida, USA;1. Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, P.O. Box 3030, Irbid, 22110, Jordan;2. Department of Legal Medicine, Toxicology and Forensic Science, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan;3. Department of Pathology and Microbiology and Forensic Medicine, University of Jordan, Amman, 11942, Jordan |
| |
| Abstract: | Palpation records of 155 Throughbred broodmares maintained on one of seven farms (3–80 mares per farm) that were administered deslorelin on one or more estrous cycles (204 treated cycles) during the 1999 breeding season were retrospectively examined. Some deslorelin-treated mares were also treated with hCG (2500 units intravenously), or had no ovulation-inducing drugs administered, during different estrous cycles of the same season. Most mares were treated with an ovulation- inducing drug after returning to their resident farm following breeding and were subsequently examined by transrectal ultrasonography daily until ovulation was confirmed, and again 13–14 and 15–16 days after ovulation for determination of pregnancy status.Per-cycle pregnancy rate for all 155 mares bred was 53%, and for all deslorelin breeding was 57%. Per-cycle pregnancy rates for mares ovulating 0–1 days, 1–2 days, and 2–3 days after treatment with deslorelin did not differ (P>0.05). Forty-six mares received more than one treatment during the breeding season, yielding 115 breedings (estrous cycles) for comparison of pregnancy rates among treatment. Per-cycle pregnancy rates for these mares did not differ among treatments (P>0.10).No differences due to treatment were detected in mean interval to ovulation (P>0.10). Mean interovulatory interval was longer for deslorelin-treated mares than for untreated or hCG treated mares (P>0.01). Eighty percent (80%) of deslorelin-treated mares had interovulatory intervals of 18–25 days, and 19% had interovulatory intervals>25 days. Ninety-seven percent (97%) of untreated or hCG-treated mares had interovulatory interovulatory intervals>25 days. More deslorelin-treated mares had extended (>25 days) interovulatory intervals than hCG- or nontreated-mares (P>0.05). In this group of Thoroughbred mares, it appeared that season (month) and management (farm) factors had only minor effects on the incidence of extended interovulatory intervals following use of deslorelin. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
